Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 1
2009 2
2010 3
2011 1
2012 3
2013 5
2014 2
2016 1
2017 3
2018 4
2019 1
2020 1
2021 4
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A. Varona JF, et al. Among authors: lubomirov r. Life Sci Alliance. 2022 Jan 10;5(4):e202101200. doi: 10.26508/lsa.202101200. Print 2022 Apr. Life Sci Alliance. 2022. PMID: 35012962 Free PMC article. Clinical Trial.
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.
Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, de Orueta LF, Torralba M, Fortún J, Vates R, Barberán J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijón P, Monereo A, Abad D, Zúñiga S, Sola I, Rodon J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Girón de Velasco P, Sopesén B, Nieto A, Gómez J, Avilés P, Lubomirov R, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, Enjuanes L, Fernández-Sousa JM; Plitidepsin – COVID - 19 Study Group; Krogan NJ, Jimeno JM, García-Sastre A. Varona JF, et al. Among authors: lubomirov r. medRxiv [Preprint]. 2021 May 25:2021.05.25.21257505. doi: 10.1101/2021.05.25.21257505. medRxiv. 2021. PMID: 34075384 Free PMC article. Updated. Preprint.
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Fudio S, Tabernero J, Subbiah V, Chawla SP, Moreno V, Longo F, Lopez R, Anton A, Trigo JM, Shapiro G, Jeong W, Villalobos VM, Lubomirov R, Fernandez-Teruel C, Alfaro V, Boni V. Fudio S, et al. Among authors: lubomirov r. Cancer Chemother Pharmacol. 2021 Jan;87(1):113-124. doi: 10.1007/s00280-020-04153-6. Epub 2020 Oct 27. Cancer Chemother Pharmacol. 2021. PMID: 33108504 Free PMC article. Clinical Trial.
Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Aviles P, Altares R, van Andel L, Lubomirov R, Fudio S, Rosing H, Márquez Del Pino FM, Tibben MM, Benedit G, Nan-Offeringa L, Luepke Estefan XE, Francesch A, Zeaiter A, Cuevas C, Schellens JHM, Beijnen JH. Aviles P, et al. Among authors: lubomirov r. Drug Metab Dispos. 2022 Apr;50(4):327-340. doi: 10.1124/dmd.121.000668. Epub 2022 Jan 18. Drug Metab Dispos. 2022. PMID: 35042701
35 results